Relmada Therapeutics IncNASDAQ:RLMD
- LAST PRICE3.0200
- TODAY'S CHANGE (%)0.0100 (0.3322%)
- Bid / Lots2.9500/ 2
- Ask / Lots3.2500/ 1
- Open / Previous Close3.0400 / 3.0100
- Day Range
- 52 Week Range
- Volume97,954
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RLMD |
|---|---|---|
| 09:32 ET | 352 | 3.04 |
| 09:36 ET | 500 | 3.05 |
| 09:45 ET | 300 | 3.0213 |
| 09:48 ET | 200 | 3.03 |
| 09:56 ET | 400 | 3.06 |
| 10:03 ET | 200 | 3.05 |
| 10:06 ET | 1900 | 3.01 |
| 10:12 ET | 600 | 3.03 |
| 10:26 ET | 100 | 3.021 |
| 10:28 ET | 2000 | 3.0301 |
| 10:30 ET | 3300 | 3.02 |
| 10:33 ET | 500 | 3 |
| 10:55 ET | 100 | 3.03 |
| 10:57 ET | 2300 | 3.02 |
| 11:00 ET | 732 | 3.01 |
| 11:04 ET | 1300 | 3 |
| 11:08 ET | 200 | 2.99 |
| 11:09 ET | 200 | 3 |
| 11:11 ET | 100 | 3 |
| 11:13 ET | 500 | 2.99 |
| 11:15 ET | 100 | 3.02 |
| 11:38 ET | 100 | 3.01 |
| 11:40 ET | 1400 | 3 |
| 11:44 ET | 121 | 3 |
| 11:45 ET | 200 | 3 |
| 11:47 ET | 2228 | 3 |
| 11:49 ET | 100 | 3 |
| 11:51 ET | 200 | 3 |
| 11:54 ET | 200 | 3 |
| 11:56 ET | 100 | 3 |
| 12:00 ET | 100 | 3 |
| 12:02 ET | 400 | 3.0079 |
| 12:05 ET | 4603 | 3 |
| 12:07 ET | 100 | 3 |
| 12:12 ET | 300 | 3 |
| 12:18 ET | 1382 | 3.01 |
| 12:20 ET | 200 | 3 |
| 12:21 ET | 222 | 3 |
| 12:23 ET | 700 | 3 |
| 12:32 ET | 100 | 3 |
| 12:34 ET | 100 | 3 |
| 12:41 ET | 100 | 3 |
| 12:45 ET | 400 | 3 |
| 12:56 ET | 100 | 3 |
| 12:57 ET | 100 | 3 |
| 01:14 ET | 683 | 3 |
| 01:19 ET | 100 | 2.99 |
| 01:21 ET | 100 | 3 |
| 01:26 ET | 3218 | 3 |
| 01:28 ET | 306 | 3 |
| 01:32 ET | 100 | 3 |
| 01:37 ET | 100 | 3 |
| 01:39 ET | 500 | 3.01 |
| 01:42 ET | 100 | 3 |
| 01:44 ET | 100 | 3 |
| 01:46 ET | 200 | 3 |
| 01:48 ET | 550 | 3.01 |
| 01:51 ET | 1040 | 3 |
| 01:57 ET | 2217 | 3.02 |
| 02:00 ET | 100 | 3.02 |
| 02:06 ET | 305 | 3.01 |
| 02:08 ET | 300 | 3.01 |
| 02:09 ET | 306 | 3 |
| 02:11 ET | 100 | 3 |
| 02:13 ET | 100 | 3 |
| 02:18 ET | 200 | 3 |
| 02:22 ET | 106 | 3 |
| 02:26 ET | 100 | 3 |
| 02:27 ET | 100 | 3.01 |
| 02:29 ET | 100 | 3.01 |
| 02:31 ET | 364 | 3 |
| 02:33 ET | 1100 | 3 |
| 02:36 ET | 214 | 3 |
| 02:38 ET | 100 | 3 |
| 02:44 ET | 200 | 3 |
| 02:45 ET | 100 | 3 |
| 02:47 ET | 208 | 3 |
| 02:51 ET | 100 | 3 |
| 02:54 ET | 100 | 3 |
| 02:56 ET | 100 | 3 |
| 02:58 ET | 100 | 3 |
| 03:00 ET | 209 | 3 |
| 03:02 ET | 100 | 3 |
| 03:03 ET | 200 | 3 |
| 03:07 ET | 100 | 3 |
| 03:09 ET | 300 | 3.01 |
| 03:14 ET | 383 | 3.01 |
| 03:16 ET | 100 | 3 |
| 03:18 ET | 100 | 3 |
| 03:20 ET | 100 | 3 |
| 03:21 ET | 100 | 3 |
| 03:23 ET | 300 | 3 |
| 03:25 ET | 100 | 3 |
| 03:27 ET | 100 | 3 |
| 03:30 ET | 100 | 3 |
| 03:32 ET | 200 | 3 |
| 03:34 ET | 100 | 3.01 |
| 03:36 ET | 111 | 3 |
| 03:38 ET | 800 | 3.025 |
| 03:39 ET | 184 | 3.02 |
| 03:41 ET | 300 | 3.02 |
| 03:43 ET | 200 | 3.01 |
| 03:48 ET | 1500 | 3.03 |
| 03:50 ET | 100 | 3.02 |
| 03:52 ET | 1852 | 3.01 |
| 03:54 ET | 25406 | 3 |
| 03:56 ET | 1424 | 3.01 |
| 03:57 ET | 1915 | 3 |
| 03:59 ET | 6617 | 3.02 |
Today
Yesterday
Jul 5, 2024
Jul 3, 2024
The Schall Law Firm Investigates Relmada Therapeutics Inc For Potential Securities Breaches And Encourages Impacted Investors To Connect, from 12:32PM ET on Wednesday Jul 03, 2024 by Dow Jones
12:32PM ET on Wednesday Jul 03, 2024 by Dow Jones
Jul 2, 2024
The Schall Law Firm Probes Relmada Therapeutics Inc For Possible Securities Violations And Urges Affected Investors To Contact, from 3:32PM ET on Tuesday Jul 02, 2024 by Dow Jones
3:32PM ET on Tuesday Jul 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Relmada Therapeutics Inc | 91.1M | -1.0x | --- |
Annovis Bio Inc | 124.0M | -2.2x | --- |
Adicet Bio Inc | 87.9M | -0.4x | --- |
Citius Pharmaceuticals Inc | 95.6M | -2.2x | --- |
Boundless Bio Inc | 92.4M | 0.0x | --- |
RAPT Therapeutics Inc | 97.4M | -0.9x | --- |
Company Information
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Contact Information
- Headquarters
- 2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES, FL, United States 33134
- Phone
- 646-876-3459
- Fax
- ---
Executives
- Independent Chairman of the Board
- Charles Casamento
- Chief Executive Officer, Director
- Sergio Traversa
- Chief Financial Officer
- Maged Shenouda
- Chief Accounting, Compliance Officer
- Charles Ence
- Acting Chief Scientific Officer
- Paolo Manfredi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $91.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-3.13 |
Book Value | $2.84 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
